Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BrainCool AB (publ) – The last exercise period for BrainCool’s warrants, BRAIN TO 1, 2017-2020, starts on Friday, November 20, 2020

As part of BrainCool´s with L1 Capital, BrainCool has distributed free warrants to the company's shareholders to reduce dilution. During the period of November 20 to December 4, 2020, holders of BRAIN TO 1 warrants can exercise the warrants and subscribe for new shares. One (1) BRAIN TO 1 warrant can be exchanged for one (1) share, at a price of 2,77 SEK. After the end of this exercise period, the warrants of series BRAIN TO 1 expire and the holders lose their right to subscribe for shares. Holders of warrants who have their warrants nominee registered in the custody of a bank or broker

Invitation: Ethics of AI webinar on 27 November

What is ethical artificial intelligence? How can public administrations and companies utilise artificial intelligence in a fair manner? These are the questions that will be explored in the webinar organised by the University of Helsinki, City of Helsinki and Finnish Centre for Artificial Intelligence on Friday 27 November. Welcome to the webinar on Friday 27 November at 1:00 p.m. – 3:00 p.m. (UTC +2) Artificial intelligence is being increasingly used to support decision-making relating to citizens. What ethical considerations must be taken into account by users and developers

Diamyd Medical will fully subscribe for its pro rata share in NextCell Pharma

Diamyd Medical will invest its pro rata share corresponding to approximately SEK 19.3 million in a rights issue in the associated company NextCell Pharma AB, which means that Diamyd Medical's book value of the holding in NextCell Pharma after the investment increases from approximately SEK 11.7 million to approximately SEK 30.9 million.Diamyd Medical is one of the main owners in NextCell Pharma with an ownership share of approximately 12.8%. The Board of Directors of NextCell Pharma has annunced its intention to decide on a fully guaranteed rights issue which, upon full subscription, will

Join Valio at digital event Fi Connect 2020: showcases about Healthy ageing, Lactose free opportunities, Milk fat and infant nutrition

The current health trend means that consumers are looking for foods that support an active and healthy lifestyle. They want to enjoy eating and are reluctant to compromise on the taste, texture, or naturality of food. At the new digital event Fi Connect 2020 in November, Valio will host three Exhibitor Showcases related to Healthy Ageing, Lactose free opportunities in dairy business, and What’s new in milk fat and infant nutrition.People are increasingly aware of the importance of health and wellbeing, and how food and good nutrition plays an important role in everyday life. As the world

The Board of Directors of NextCell Pharma intends on resolving on a fully guaranteed preferential rights issue of approximately SEK 150 million

The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) today announces its intention to resolve on a fully guaranteed rights issue of up to approximately SEK 150 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The Board of Directors’ intent to resolve on the Rights Issue requires that the shareholders at the Annual General Meeting on 24 November 2020 authorizes the Board of Directors to resolve on share issues. In the notice convening the Annual General Meeting, which was published by press release on 23 October 2020, the

INITIATOR PHARMA: Q3 2020 report

Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016. Third Quarter (2020-07-01 – 2020-09-30) · Net revenues were TDKK 0 (0) · EBIT was TDKK -3,068 (-1,969) · Earnings per share was DKK –0.12 (-0.08) First Nine Months of the Year (2020-01-01 – 2020-09-30) · Net revenues were TDKK 0 (0) · EBIT was TDKK -8,462 (-6,836) · Earnings per share was DKK –0.35 (-0.28) · Cash and bank: TDKK 8,174 (12,223) · Solidity:

Veidekke ASA: Modernising student homes in Oslo

Veidekke’s subsidiary Seby AS shall rehabilitate and remodel 176 apartments in Sogn Studentby for the student welfare organisation SiO. The contract is a design and build contract with interaction and the preliminary contract total is estimated at NOK 130 million excluding VAT.The contract involves internal remodelling of existing apartments in two student home buildings. This primarily involves remodelling from shared apartments where four to five people have shared a kitchen and bathroom, to one-bedroom apartments with their own bathrooms and kitchens. Furthermore, balanced ventilation is

Crown Energy AB: Interim Report January-September 2020

Q3 – JULY-SEPTEMBER 2020 · Revenue amounted to SEK SEK 6,993 thousand (13,327). · Operating profit amounted to SEK -1,283 thousand (2,528). · Net financial items amounted to SEK 6,679 thousand (27,361). · Unrealised changes in property values amounted to SEK -8,854 thousand (796). · Profit before tax amounted to SEK -3,458 thousand (30,686), and profit after tax amounted to SEK -4,731 thousand (28,569), corresponding to SEK -0.01 (0.06) per share. NINE MONTH PERIOD– JANUARY-SEPTEMBER 2020 · Revenue amounted to SEK 24,347 thousand (38,865). · Operating loss

Correction of date for Ericsson’s fourth quarter report 2020

Ericsson's (NASDAQ: ERIC) financial report for the fourth quarter 2020, will be issued on January 29, 2021. By mistake an incorrect date is stated in the financial report for the third quarter of 2020, published on October 21. The error occurs on page 12, last sentence, “Date for next report: January 26, 2021”. FOLLOW US: Subscribe to Ericsson press releases here . Subscribe to the Ericsson Blog here . www.twitter.com/ericssonwww.facebook.com/ericsson

Final report submitted to the Estonian Financial Supervisory Authority

Swedbank AS has submitted a final report describing the actions taken to comply with the precept of the Estonian Financial Supervision and Resolution Authority (EFSA) which was issued on March 18, 2020.The report addresses historic shortcomings that were presented in the precept and reflects the full commitment of Swedbank Group to establish systems, controls and solutions for anti-money laundering (AML) and counter-terrorist financing (CTF) purposes. “We believe that we have closed the shortcomings identified by the EFSA. But we are not leaving the lessons learnt behind us. We are fully

Agder Energi Nett renews agreement with Rejlers Elsikkerhet

Energy distribution company Agder Energi Nett is renewing its agreement concerning inspection services in Agder, West. The agreement commences on 1 January 2021 and will run for two years, with the possibility of extension for a further three years.Rejlers will be responsible for carrying out inspections in the area in close cooperation with the Local Electrical Safety Inspection Authorities (DLE). The tasks range from electrical inspections of residential properties to audits of businesses and electrical contractors, as well as information dissemination. "We are very pleased to have had

Imfinzi new dosing approved in the US

20 November 2020 07:00 GMT Imfinzi approved in the US for less-frequent, fixed-dose use Four-week dosing now approved in all Imfinzi indications, reducing medical visits and improving patient convenience   AstraZeneca's Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy (CRT) and previously treated advanced bladder cancer. This new option is consistent with the approved Imfinzi dosing in

Flexion Mobile launches Taptap Heroes

LONDON, 20th of November, 2020 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company today announced that Taptap Heroes from Ajoy Lab Games has been launched on Amazon and Samsung. Taptap Heroes is a very popular casual and strategic role play game (RPG) which was launched in Google Play in May 2018. According to Sensor Tower the game generated USD 800,000 on Google Play in net revenues in October. "It is great to celebrate the launch of Taptap Heroes - our 20th live game! I am proud to say that it only took us five weeks from signing to launch. We look forward to

FluoGuide A/S publishes interim report for the period January – September 2020

Copenhagen, Denmark, 20 November 2020 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 30 September 2020. The interim report is available as an attached document to this press release and on  https://fluoguide.com/investor/filings-reports/.Third quarter 2020 (1 July – 30 September): · Net revenue was KDKK 0 (0) · Operating result was KDKK -3,123 (-5,057) · Net result was KDKK -2,299 (-4,047) · Cash and bank was KDKK 18,214 (9,630) · Result per share* was DKK -0.22 (-0.56) · Solidity** was 50% (65%) First nine months

Interim report: Successful directed share issue

Based on a directed share issue of 12.3 million new shares, the company received proceeds of approximately SEK 270 million before issue expenses. Several new Swedish and international institutional investors as well as certain existing shareholders subscribed for shares in the issue. The proceeds will be used to finance the company’s ongoing operations and the continued industrialisation of Azelio’s Thermal Energy Storage (TES) and Stirling-based electricity production technology, with the objective of reaching industrial volume production in 2021. The company continued to sign Memorandums

DBP International AB: The stability study has been started

Double Bond Pharmaceutical International AB ("DBP") reports that the stability studies for SI-053 have been started. The study is conducted by a company specializing in manufacturing and stability processes and is located within the EU. The studies required for CTA regarding the stability of SI-053 have now been completed and will be added to the regulatory documentation, IMPD. "This enormous milestone takes us one step closer to clinical phase 1. With this, we can state that the product is stable, sterile and can be used safely and securely in humans." - comments Sayeh Erfan, Director

American Shipping Company ASA - Third quarter financial results

Lysaker, 20 November 2020, American Shipping Company ASA (“AMSC” or the “Company”) announces results for third quarter ending 30 September 2020. HIGHLIGHTS · Completed refinancing of the Company’s USD 220 million unsecured bond, with a new USD 200 million bond, at a 7.75% coupon, 150 basis points lower coupon than the prior bond · Stable Q3 financial performance with bareboat revenue of USD 22.2 million, normalized EBITDA of USD 22.4 million and adjusted net profit of USD 4.6 million · Backlog of secured bareboat revenue of USD 256 million with average weighted tenor of 2.9

Invitation to analyst presentation of the quarterly report for Q3

On Thursday, November 26, at 3 pm, the quarterly report for Cabonline Group Holding AB (publ) (the "Company") for the period January-September 2020 will be published. For analysts, there will be an opportunity for presentation meetings on Friday, November 27, 2020.Cabonlines' acting CEO and CFO, Anneli Lindblom, is available for digital meetings with analysts on Friday 27 November. To book a meeting, please contact Sofia Myrevik, Group Communications; sofia.myrevik@cabonline.com or +46 70-341 46 38.

Clavister Holding AB publishes final outcome of its rights issue and directed share issue

Clavister Holding AB (”Clavister” or the “Company”) raises through the Rights Issue and the Direct Issue approx. SEK 204 million before deduction of issue related costs, which was resolved by the extra general meeting on 22 October 2020. SEK 149.8 million was raised through its rights issue (the “Rights Issue”). The final outcome of Clavister’s Rights Issue show that approx. 59 % of the Rights Issue, corresponding to approx. SEK 88.7 million, were subscribed for with preferential rights (incl. subscription undertakings). Additionally, approx. 8 % of the Rights Issue, corresponding to approx.

Exercise of options  Issue of equity

Company announcement, 20 November 2020 at 9.00 (EET) TURKU, FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that it has received notifications from option holders to exercise D options over 82,000 ordinary shares in the Company at an exercise price of EUR 1.09 (approx. GBP 0.97) per share under the Company’s 2015 Option Plan (“New Ordinary Shares”). The terms and conditions of the 2015 Option Plan are available on the Company’s website at https://www.faron.com/sites/default/files/Option%20Plan%202015_Terms%20and%

Interim Report January – September 2020

Significant events during the third quarter 2020 · Whittle Consulting is working on the Blötberget optimisation study. · A short-term loan amounting to SEK 5 million was raised in August. Third quarter, 1 July – 30 September 2020 · Income amounted to SEK 0 million (0) · Earnings after tax amounted to SEK – 2.4 million (–3.1) · Investments in the period July - September totalled SEK 1.5 million (3.3) · Basic earnings per share were SEK –0.08 (–0.15) Interim period, 1 January – 30 September 2020 · Income amounted to SEK 0 million (0) · Earnings after tax

TYRI Delivers TYRI INTELLilight™ to BELAZ

TYRI's has signed the first major deal for their new intelligent lighting system TYRI INTELLilight, with BELAZ, a world-leading manufacturer of dump trucks. BELAZ has placed an order for 100 TYRI INTELLilight™ systems to be installed on its 270-tonne trucks. Manufacturing and delivery will begin in 2020.This deal is the first major implementation for TYRI’s new lighting system TYRI INTELLilight™, which was launched earlier this year. The system was thoroughly tested by BELAZ over the period of a year before the contract was agreed. BELAZ’s requirements included the integration of the

ZINZINO AB (PUBL): INTERIM REPORT THIRD QUARTER 2020

HISTORICAL ALL-TIME HIGH FOR ZINZINO – WE’RE INCREASING THE PROFIT FORECAST SIGNIFICANTLYThe third quarter 2020 was the strongest quarter in the company’s history in terms of sales. Total revenues in the Group increased by 51% and amounted to SEK 281.8 (186.5) million. This is due to sales growth in all regions. The strongest growth continued to be in the Central European countries, but North America also increased significantly during the quarter. Profitability was also very good and the EBITDA result amounted to SEK 28.8 (4.4) million for the quarter. The EBITDA margin consequently

There are no items matching the current filter
There are no more items matching the current filter
Back to top